Document is current
Any future updates will be listed below
-
Authors
Hosseini, Fatemeh S. https://orcid.org/0000-0002-6941-6480
Laurencin, Cato T. https://orcid.org/0000-0001-6765-3047
-
Funding
Funding for this research was provided by:
National Institute for Health Care Management Foundation (T32 AR050960, DE029316-01 602040)
- License Information
-
More Information
Article History
Received: 25 May 2022
Revised: 27 July 2022
Accepted: 11 August 2022
First Online: 24 August 2022
Declarations
:
: Dr. Cato T. Laurencin is the editor-in-chief of Regenerative Engineering and Translational Medicine. Dr. Cato Laurencin has the following competing financial interests: Mimedx, Alkermes Company, Biobind, Soft Tissue Regeneration/Biorez, and Healing Orthopaedic Technologies-Bone.
